Cognitive Impairment and Return to Work in Long COVID
NCT07881029, Completed, Hopitaux de Saint-Maurice
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cognitive Impairment and Return to Work in Long COVID | ClinicalTrials.gov |
| NCT number | NCT07881029 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 55 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Hopitaux de Saint-Maurice | ClinicalTrials.gov |
| Conditions | Long COVID | ClinicalTrials.gov |
| First posted | 2026-10-19 | ClinicalTrials.gov |
| Last updated | 2026-10-19 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Processing Speed According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Processing speed assessed using the Coding subtest of the WAIS-IV at the neuropsychological assessment, compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Primary | Verbal Short-Term Memory According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Verbal short-term memory assessed using the auditory-verbal span from the WAIS-IV, compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Primary | Visual Short-Term Memory According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Visual short-term memory assessed using the visuospatial span from the MEM-III, compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Primary | Long-Term Verbal Memory According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Long-term verbal memory was assessed using the RL/RI-16 test. Measures included retrieval (sum of the three free-recall trials), storage (sum of the three total-recall trials and recognition), and long-term consolidation (delayed free and total recall). Performance was compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Primary | Selective Attention According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Selective attention was assessed using the D2 or D2-R test, based on response accuracy and errors. Performance was compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Primary | Sustained Attention According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Sustained attention was assessed using the D2 or D2-R test, based on concentration performance. Performance was compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Primary | Mental Flexibility According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Mental flexibility was assessed using the Trail Making Test (TMT), including errors on Part B and the B-A completion-time difference. Performance was compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Primary | Inhibition According to Return-to-Work Status at 6 Months | From the neuropsychological assessment to 6-month follow-up | Inhibitory control was assessed using the Stroop Test, including errors on the interference condition and the interference time adjusted for naming time. Performance was compared according to return-to-work status at 6 months. | ClinicalTrials.gov |
| Secondary | Frequency of Below-Norm Cognitive Performance by Domain Using Standardized Neuropsychological Tests | Baseline | Frequency of participants with cognitive performance below normative values in each assessed domain. Processing speed was assessed with the WAIS-IV Coding subtest; verbal short-term memory with the WAIS-IV auditory-verbal span; visual short-term memory with the MEM-III visuospatial span; long-term verbal memory with the RL/RI-16; selective and sustained attention with the D2/D2-R; and executive functions with the Trail Making Test and Stroop Test. Classification as below normative values was based on the normative interpretation applicable to each test. | ClinicalTrials.gov |
| Secondary | Number of Participants According to Return-to-Work Status at 6 Months | 6 months after the neuropsychological assessment | Number of participants according to return-to-work status at 6-month follow-up: return to work or no return to work. Among participants who returned to work, partial and full return to work will also be described. | ClinicalTrials.gov |
| Secondary | Cognitive Performance According to Employment Status at Neuropsychological Assessment and at 6 Months | From the neuropsychological assessment to 6-month follow-up | Cognitive performance was assessed using standardized neuropsychological tests covering processing speed (WAIS-IV Coding), verbal short-term memory (WAIS-IV auditory-verbal span), visual short-term memory (MEM-III visuospatial span), long-term verbal memory (RL/RI-16), attention (D2/D2-R), mental flexibility (Trail Making Test), and inhibition (Stroop Test). Performance was compared according to employment status at the neuropsychological assessment and at 6-month follow-up. | ClinicalTrials.gov |
| Secondary | Anxiety Symptoms Assessed With the State-Trait Anxiety Inventory (STAI) | Baseline | Anxiety symptoms were assessed using the State-Trait Anxiety Inventory (STAI), including state and trait anxiety measures. | ClinicalTrials.gov |
| Secondary | Depressive Symptoms Assessed With the Beck Depression Inventory (BDI) | Baseline | Depressive symptoms were assessed using the Beck Depression Inventory (BDI). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)